ID-Migraine test for pediatric population: preliminary results from the Italian validation
Accepted: 14 April 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Migraine is a frequent neurological condition with a high impact on quality life. The diagnosis is clinical in accordance with the International Classification of Headache Disorders version 3 criteria. Early diagnosis is important to initiate timely treatment. A screening tool for adulthood is already available (ID-Migraine), while there is currently no questionnaire that allows for diagnosis in children and adolescents. The aim of the present study is to demonstrate the validity of ID-Migraine to diagnose migraine in pediatric population.
Methods: A total of 94 pediatric patients were enrolled and administered ID-Migraine. The mean age was 11.6 years. The study group included patients with a diagnosis of migraine (63%) and primary stabbing headache (37%).
Results and conclusions: Specificity and positive predictive values were >80% (92% and 93% respectively); sensitivity and negative predictive values tended towards reliability (71% and 66% respectively), making the ID-Migraine a reliable tool in diagnosing migraine in the pediatric population.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.